Latanoprost-Timolol Ab (Timolol Maleate, Latanoprost)

Timolol maleate is a non‑selective beta‑adrenergic blocker that reduces aqueous humor production by inhibiting β‑receptors in the ciliary epithelium. Latanoprost is a prostaglandin F2α analog that increases uveoscleral outflow of aqueous humor through FP‑receptor activation. The combination provides a dual mechanism that more effectively lowers intra‑ocular pressure than either component alone.

The prescribed dose is determined by the treating ophthalmologist. In clinical practice the medication is typically instilled as one drop in the affected eye(s) once daily, usually in the evening, but exact dosing and timing should follow the prescriber’s instructions.

Safety data for use in pregnancy and lactation are limited. The product should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Physicians should discuss individual risk factors with the patient before initiating therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with monotherapy agents such as timolol alone or latanoprost alone, the fixed‑combination provides greater intra‑ocular pressure reduction because it targets both production and outflow pathways. It may be preferred when single‑agent therapy does not achieve target pressure, offering convenience of a single drop rather than multiple medications.

Store the eye‑drop bottles below 25 °C in the original packaging, protecting them from light, moisture and extreme temperature fluctuations. Do not freeze the product. Keep the container tightly closed when not in use and discard any solution that appears discolored or contaminated.

Wash hands thoroughly, tilt the head back slightly, and pull down the lower eyelid to form a pocket. Instill one drop into the conjunctival sac without touching the tip of the bottle to the eye or lashes. Close the eye gently for a few seconds and avoid blinking excessively. Repeat in the other eye if prescribed.

Serious adverse events include severe allergic reactions (e.g., swelling, rash, anaphylaxis), marked bradycardia or bronchospasm especially in patients with pre‑existing cardiac or respiratory disease, and persistent changes in iris pigmentation. Any of these symptoms require immediate medical evaluation.

The product is contraindicated in patients with known hypersensitivity to timolol, latanoprost, or any excipients, as well as in individuals with severe sinus bradycardia, second‑ or third‑degree atrioventricular block, uncompensated heart failure, or active asthma/COPD where beta‑blockade could worsen airway obstruction.